AIM:IXI

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

UK£41.7m

Last Updated

2021/06/17 23:02 UTC

Data Sources

Company Financials

Executive Summary

IXICO plc provides data analytics services to the biopharmaceutical industry in the United States, the United Kingdom, Europe, and internationally. More Details


Snowflake Analysis

Flawless balance sheet and good value.

Share Price & News

How has IXICO's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IXI is more volatile than 90% of UK stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: IXI's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of UK stocks.


Market Performance


7 Day Return

3.6%

IXI

-2.6%

GB Life Sciences

0.1%

GB Market


1 Year Return

38.1%

IXI

22.7%

GB Life Sciences

18.7%

GB Market

Return vs Industry: IXI exceeded the UK Life Sciences industry which returned 31.4% over the past year.

Return vs Market: IXI exceeded the UK Market which returned 22% over the past year.


Shareholder returns

IXIIndustryMarket
7 Day3.6%-2.6%0.1%
30 Day3.6%-9.5%1.4%
90 Day-16.3%-8.5%7.2%
1 Year38.1%38.1%23.3%22.7%24.6%18.7%
3 Year155.9%155.9%28.7%26.8%14.5%1.3%
5 Year167.7%167.7%81.3%77.9%47.6%19.9%

Long-Term Price Volatility Vs. Market

How volatile is IXICO's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is IXICO undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: IXI (£0.85) is trading below our estimate of fair value (£1.9)

Significantly Below Fair Value: IXI is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: IXI is good value based on its PE Ratio (30.2x) compared to the UK Life Sciences industry average (64.9x).

PE vs Market: IXI is poor value based on its PE Ratio (30.2x) compared to the UK market (25.9x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IXI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IXI is good value based on its PB Ratio (3.9x) compared to the GB Life Sciences industry average (4.6x).


Future Growth

How is IXICO forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

16.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as IXICO has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has IXICO performed over the past 5 years?

66.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IXI has a high level of non-cash earnings.

Growing Profit Margin: IXI's current net profit margins (13.3%) are higher than last year (8%).


Past Earnings Growth Analysis

Earnings Trend: IXI has become profitable over the past 5 years, growing earnings by 66.3% per year.

Accelerating Growth: IXI's earnings growth over the past year (90.6%) exceeds its 5-year average (66.3% per year).

Earnings vs Industry: IXI earnings growth over the past year (90.6%) exceeded the Life Sciences industry -8.5%.


Return on Equity

High ROE: IXI's Return on Equity (12.7%) is considered low.


Financial Health

How is IXICO's financial position?


Financial Position Analysis

Short Term Liabilities: IXI's short term assets (£10.5M) exceed its short term liabilities (£2.3M).

Long Term Liabilities: IXI's short term assets (£10.5M) exceed its long term liabilities (£707.0K).


Debt to Equity History and Analysis

Debt Level: IXI is debt free.

Reducing Debt: IXI has not had any debt for past 5 years.

Debt Coverage: IXI has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: IXI has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is IXICO current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IXI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IXI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IXI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IXI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IXI's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average management tenure


CEO

Giulio Cerroni (59 yo)

4.33yrs

Tenure

UK£537,660

Compensation

Mr. Giulio Cerroni has been Chief Executive Officer of IXICO Plc since February 6, 2017 and serves as its Director. Mr. Cerroni has almost 30 years of international management experience gained in life sci...


CEO Compensation Analysis

Compensation vs Market: Giulio's total compensation ($USD758.40K) is above average for companies of similar size in the UK market ($USD334.43K).

Compensation vs Earnings: Giulio's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: IXI's management team is considered experienced (4.3 years average tenure).


Board Members

Experienced Board: IXI's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: IXI insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

IXICO plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: IXICO plc
  • Ticker: IXI
  • Exchange: AIM
  • Founded: 1995
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£41.733m
  • Shares outstanding: 47.97m
  • Website: https://www.ixico.com

Number of Employees


Location

  • IXICO plc
  • Griffin Court
  • 4th Floor
  • London
  • Greater London
  • EC1A 9PN
  • United Kingdom

Listings


Biography

IXICO plc provides data analytics services to the biopharmaceutical industry in the United States, the United Kingdom, Europe, and internationally. It provides collection, analysis, management, and reporti...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/17 23:02
End of Day Share Price2021/06/17 00:00
Earnings2021/03/31
Annual Earnings2020/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.